Klaria Pharma Holding AB (publ.) (KLAR.ST)
SEK 1.17
(-4.12%)
SEK 1.17
(-4.12%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | - SEK | 0.0% |
| 2022 | - SEK | 100.0% |
| 2021 | -14 Thousand SEK | 99.19% |
| 2020 | -1.72 Million SEK | -35.94% |
| 2019 | -1.26 Million SEK | 20.78% |
| 2018 | -1.59 Million SEK | -63.06% |
| 2017 | -980 Thousand SEK | -21.29% |
| 2016 | -808 Thousand SEK | 31.53% |
| 2015 | -1.18 Million SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | - SEK | 0.0% |
| 2024 Q2 | - SEK | 0.0% |
| 2023 Q1 | - SEK | 0.0% |
| 2023 Q2 | - SEK | 0.0% |
| 2023 Q3 | - SEK | 0.0% |
| 2023 Q4 | - SEK | 0.0% |
| 2023 FY | - SEK | 0.0% |
| 2022 Q3 | -2.46 Million SEK | 73.77% |
| 2022 FY | - SEK | 100.0% |
| 2022 Q2 | -9.4 Million SEK | -39.0% |
| 2022 Q1 | -6.76 Million SEK | -48235.71% |
| 2022 Q4 | - SEK | 100.0% |
| 2021 Q3 | -1.94 Million SEK | 20.52% |
| 2021 Q2 | -2.45 Million SEK | -48.73% |
| 2021 FY | -14 Thousand SEK | 99.19% |
| 2021 Q1 | -1.64 Million SEK | -6003.7% |
| 2021 Q4 | -14 Thousand SEK | 99.28% |
| 2020 Q2 | - SEK | 100.0% |
| 2020 FY | -1.72 Million SEK | -35.94% |
| 2020 Q4 | -27 Thousand SEK | 0.0% |
| 2020 Q1 | -1.76 Million SEK | 0.0% |
| 2020 Q3 | - SEK | -100.0% |
| 2019 Q3 | -1.21 Million SEK | -121800099.77% |
| 2019 Q2 | 1.00 SEK | 100.0% |
| 2019 Q1 | -1.03 Million SEK | -886.67% |
| 2019 FY | -1.26 Million SEK | 20.78% |
| 2019 Q4 | - SEK | 100.0% |
| 2018 Q1 | - SEK | 0.0% |
| 2018 Q3 | -996 Thousand SEK | 0.0% |
| 2018 FY | -1.59 Million SEK | -63.06% |
| 2018 Q4 | -105 Thousand SEK | 89.46% |
| 2018 Q2 | - SEK | 0.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2017 FY | -980 Thousand SEK | -21.29% |
| 2017 Q1 | - SEK | 0.0% |
| 2017 Q4 | - SEK | -100.0% |
| 2017 Q3 | - SEK | 0.0% |
| 2016 Q4 | - SEK | 0.0% |
| 2016 FY | -808 Thousand SEK | 31.53% |
| 2016 Q3 | - SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2015 FY | -1.18 Million SEK | 0.0% |
| 2015 Q3 | -331 Thousand SEK | 0.0% |
| 2015 Q4 | - SEK | 100.0% |
| 2014 FY | - SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| AcuCort AB | -1.09 Million SEK | 100.0% |
| AlzeCure Pharma AB (publ) | -2508.00 SEK | 100.0% |
| BioGaia AB (publ) | 181.2 Million SEK | 100.0% |
| Enzymatica AB (publ) | 11.49 Million SEK | 100.0% |
| Enorama Pharma AB (publ) | 4.29 Million SEK | 100.0% |
| Gabather AB (publ) | -1772.00 SEK | 100.0% |
| Moberg Pharma AB (publ) | 7.11 Million SEK | 100.0% |
| Nanexa AB (publ) | 1.91 Million SEK | 100.0% |
| Newbury Pharmaceuticals AB (publ) | 4.99 Million SEK | 100.0% |
| ODI Pharma AB | - SEK | NaN% |
| Orexo AB (publ) | 42.4 Million SEK | 100.0% |
| Probi AB (publ) | 116.7 Million SEK | 100.0% |
| Swedencare AB (publ) | 398.1 Million SEK | 100.0% |
| Swedish Orphan Biovitrum AB (publ) | 3.87 Billion SEK | 100.0% |
| Toleranzia AB | -1.34 Million SEK | 100.0% |
| Vivesto AB | - SEK | NaN% |